C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
申请人:Karanewsky S. Donald
公开号:US20050020504A1
公开(公告)日:2005-01-27
This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.
C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES
申请人:Idun Pharmaceuticals, Inc.
公开号:EP1351975A2
公开(公告)日:2003-10-15
US7053056B2
申请人:——
公开号:US7053056B2
公开(公告)日:2006-05-30
US7183260B2
申请人:——
公开号:US7183260B2
公开(公告)日:2007-02-27
[EN] C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES<br/>[FR] OXAMYL DIPEPTIDES MODIFIES C-TERMINAL EN TANT QU'INHIBITEURS DE LA FAMILLE ICE/CED-3 DES CISTEINES PROTEASES
申请人:IDUN PHARMACEUTICALS INC
公开号:WO2002057298A2
公开(公告)日:2002-07-25
This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.